The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection

Thushan I. de Silva(Sheffield Teaching Hospitals NHS Foundation Trust), Julia Greig(Sheffield Teaching Hospitals NHS Foundation Trust), Alethea Cope(Royal Hallamshire Hospital), J R Goepel(Royal Hallamshire Hospital)
Journal of Infection
December 30, 2006
10.1016/j.jinf.2006.11.005
Cited by 21

Related Papers

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
|Nature Immunology|2020|1.4k
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
|Nature Microbiology|2022|724
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
|Cell Host & Microbe|2020|354
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
|The Lancet|2017|186
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
|EBioMedicine|2022|121